

# Jake S O'donnell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8598685/publications.pdf>

Version: 2024-02-01

15  
papers

3,266  
citations

623734

14  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

5938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer immunoeediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 2019, 16, 151-167.	27.6	1,093
2	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discovery, 2016, 6, 1382-1399.	9.4	592
3	Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 2017, 52, 71-81.	7.7	437
4	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 2018, 48, 91-103.	9.6	257
5	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	14.3	207
6	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. Clinical Cancer Research, 2019, 25, 5743-5751.	7.0	129
7	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 2020, 180, 895-914.e27.	28.9	127
8	Tumor intrinsic and extrinsic immune functions of CD155. Seminars in Cancer Biology, 2020, 65, 189-196.	9.6	85
9	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology, 2019, 8, e1581530.	4.6	69
10	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. Oncoimmunology, 2018, 7, e1431088.	4.6	67
11	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. Genome Medicine, 2016, 8, 111.	8.2	59
12	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	7.0	53
13	Batf3 <sup>+</sup> DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. Oncoimmunology, 2019, 8, e1546068.	4.6	42
14	The voltage gated Ca <sup>2+</sup> -channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell International, 2016, 16, 24.	4.1	34
15	PD1 functions by inhibiting CD28-mediated co-stimulation. Clinical and Translational Immunology, 2017, 6, e138.	3.8	15